Table 1 Clinicopathologic characteristics by constructed molecular subtype

Age, years

0.28

Median

(range)

51

(29 to 83)

51

(27 to 72)

49

(26 to 65)

49

(27 to 76)

Clinical T-stage

0.09

T0

1 (0.3%)

0

0

0

T1

65 (21%)

5 (10%)

6 (14%)

19 (10%)

T2

207 (67%)

36 (70%)

33 (79%)

140 (73%)

T3

25 (8%)

5 (10%)

3 (7%)

22 (11%)

T4

10 (3%)

5 (10%)

0

12 (6%)

Tx

1 (0.3%)

0

0

0

Clinical N-stage

0.03

N0

167 (54%)

29 (57%)

11 (26%)

101 (52%)

N1

110 (36%)

15 (29%)

23 (55%)

62 (32%)

N2

12 (4%)

1 (2%)

4 (9.5%)

9 (5%)

N3

20 (6%)

6 (12%)

4 (9.5%)

21 (11%)

Clinical stage

0.18

I

26 (8%)

4 (8%)

2 (5%)

8 (4%)

II

234 (76%)

35 (69%)

30 (71%)

137 (71%)

II

50 (16%)

12 (23%)

10 (24%)

48 (25%)

Nuclear grade

< 0.001

1

15 (5%)

1 (2%)

0

0

2

144 (47%)

14 (28%)

3 (7%)

21 (11%)

3

149 (48%)

36 (70%)

39 (93%)

172 (89%)

Unknown

1 (0.3%)

0

0

0

LVI

0.47

Yes

55 (18%)

5 (10%)

7 (17%)

28 (15%)

No

254 (82%)

46 (90%)

35 (83%)

165 (85%)

Pathologic tumor size, cm

< 0.001

Median

(range)

1.5

(0 to 9)

1.1

(0 to 4)

0.1

(0 to 8)

0.3

(0 to 5.5)

Number positive lymph nodes

0

152 (49%)

34 (67%)

27 (64%)

149 (77%)

< 0.001

1-3

103 (33%)

9 (18%)

11 (26%)

32 (17%)

≥ 4

53 (17%)

6 (12%)

4 (10%)

12 (6%)

Unknown

1 (0.3%)

2 (3%)

0

0

Number lymph nodes sampled

0.04

Median

(range)

12

(0 to 40)

5

(0 to 27)

13

(1 to 37)

9

(1 to 30)

pCR

< 0.001

Yes

27 (9%)

9 (18%)

15 (36%)

73 (38%)

No

282 (91%)

42 (18%)

27 (64%)

120 (62%)